Viewing Study NCT01808950


Ignite Creation Date: 2025-12-24 @ 5:18 PM
Ignite Modification Date: 2026-02-23 @ 9:21 PM
Study NCT ID: NCT01808950
Status: TERMINATED
Last Update Posted: 2016-06-22
First Post: 2013-03-05
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Efficacy and Safety Trial of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma
Sponsor: Spirig Pharma Ltd.
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Nodular Basal Cell Carcinoma View
Keywords: